538965 Stock Overview
Engages in the manufacture and sale of pharmaceutical formulations in India.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 1/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Concord Drugs Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹37.53 |
52 Week High | ₹61.50 |
52 Week Low | ₹30.59 |
Beta | 0.37 |
11 Month Change | 0.54% |
3 Month Change | 7.54% |
1 Year Change | 12.47% |
33 Year Change | 20.29% |
5 Year Change | 108.50% |
Change since IPO | 87.74% |
Recent News & Updates
Recent updates
Shareholder Returns
538965 | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | -1.2% | -0.6% | 0.8% |
1Y | 12.5% | 51.3% | 36.2% |
Return vs Industry: 538965 underperformed the Indian Pharmaceuticals industry which returned 51.3% over the past year.
Return vs Market: 538965 underperformed the Indian Market which returned 36.2% over the past year.
Price Volatility
538965 volatility | |
---|---|
538965 Average Weekly Movement | 5.0% |
Pharmaceuticals Industry Average Movement | 6.3% |
Market Average Movement | 6.2% |
10% most volatile stocks in IN Market | 9.3% |
10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 538965 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 538965's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1995 | 185 | Seelam Reddy | concorddrugs.in |
Concord Drugs Limited engages in the manufacture and sale of pharmaceutical formulations in India. It offers tissue bio-adhesive products. The company also provides ready-to-fill pellets and multiple unit pellets system; drugs in the form of tablets, capsules, small volume parenterals, dry powders, syrups and suspension, and dry syrups; and hand sanitizers.
Concord Drugs Limited Fundamentals Summary
538965 fundamental statistics | |
---|---|
Market cap | ₹385.80m |
Earnings (TTM) | ₹92.00k |
Revenue (TTM) | ₹476.36m |
4,079x
P/E Ratio0.8x
P/S RatioIs 538965 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
538965 income statement (TTM) | |
---|---|
Revenue | ₹476.36m |
Cost of Revenue | ₹364.87m |
Gross Profit | ₹111.49m |
Other Expenses | ₹111.40m |
Earnings | ₹92.00k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.0092 |
Gross Margin | 23.41% |
Net Profit Margin | 0.019% |
Debt/Equity Ratio | 51.8% |
How did 538965 perform over the long term?
See historical performance and comparison